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0959-8049/ª 2016 Elsevier Ltd. All righAbstract Background: Early palliative care (EPC) in oncology has been shown to have a
positive impact on clinical outcome, quality-of-care outcomes, and costs. However, the
optimal way for activating EPC has yet to be defined.
Methods: This prospective, multicentre, randomised study was conducted on 207 outpatients
with metastatic or locally advanced inoperable pancreatic cancer. Patients were randomised to
receive ‘standard cancer care plus on-demand EPC’ (n Z 100) or ‘standard cancer care plus
systematic EPC’ (n Z 107). Primary outcome was change in quality of life (QoL) evaluated
through the Functional Assessment of Cancer Therapy e Hepatobiliary questionnaire be-
tween baseline (T0) and after 12 weeks (T1), in particular the integration of physical, func-
tional, and Hepatic Cancer Subscale (HCS) combined in the Trial Outcome Index (TOI).nd Clinical Trials Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS,




M. Maltoni et al. / European Journal of Cancer 65 (2016) 61e6862Patient mood, survival, relatives’ satisfaction with care, and indicators of aggressiveness of
care were also evaluated.
Findings: The mean changes in TOI score and HCS score between T0 and T1 were 4.47 and
0.63, with a difference between groups of 3.83 (95% confidence interval [CI] 0.10e7.57)
(p Z 0.041), and 2.23 and 0.28 (difference between groups of 2.51, 95% CI 0.40e4.61,
p Z 0.013), in favour of interventional group. QoL scores at T1 of TOI scale and HCS were
84.4 versus 78.1 (pZ 0.022) and 52.0 versus 48.2 (pZ 0.008), respectively, for interventional
and standard arm. Until February 2016, 143 (76.9%) of the 186 evaluable patients had died.
There was no difference in overall survival between treatment arms.
Interpretations: Systematic EPC in advanced pancreatic cancer patients significantly improved
QoL with respect to on-demand EPC.
ª 2016 Elsevier Ltd. All rights reserved.1. Introduction
Over the years, the palliative care (PC) professional
community has attempted to change howPC is conceived,
offering an interpretation that is not limited to hospice or
end-of-life care. Although there is, in fact, more than one
‘definition’ for PC [1], it is acknowledged that it can be
subdivided in two major areas: ‘early’ palliative care
(EPC) and ‘end-of-life’ palliative care (EoL PC). EPC is
mainly delivered through PC clinics for outpatients or
through PC consultations for patients in inpatient units.
EoL PC is more often performed in inpatient hospice and
PC units. Although some regard ‘home care hospice
programmes’ as a form of EPC [1], this is open to debate.
For the purposes of this study, the concept of home care
hospice programmes is considered a part of EoL PC.
Different outcomes have been studied for EPC, e.g.
improved quality of life (QoL), better healthcare, and
lower costs [2]. Results from several original studies and
systematic reviews showed evidence in favour of EPC
together with best anticancer treatment compared to the
latter alone, although data were not uniformly positive
[1,3e6]. When this study began, the presence of EPC in
the management of advanced cancer patients was
generally accepted [7] and it would have been anachro-
nistic to consider a ‘best anticancer treatment only’ arm
as the standard arm.
In clinical practice, however, oncologists tend to
request the intervention of EPC professionals only when
they feel that a situation is too complex to manage
alone. One could say that the standard arm in oncology
for EPC has become the ‘best anticancer treatment plus
on-demand EPC’. We considered the interventional arm
as the best anticancer treatment plus systematic EPC,
defined as planned, systematic EPC together with stan-
dard cancer care starting from the diagnosis of meta-
static disease. PC, although in different ways, is so
performed in both arms, as it was in the previous studies
from other authors [4,5]. Reasonably, the first on-de-
mand PC intervention is almost never an isolated event,
with EPC subsequently performed on a continuous basisto manage the needs of the patient also in the ‘on-de-
mand’ approach.
We chose to evaluate patients with a highly lethal
tumour such as pancreatic cancer. The 2008 global
cancer incidence estimates ranked pancreatic cancer as
13th of the 20 most commonly diagnosed cancers
worldwide (2%, about 250,000) [8]. In 2014, pancreatic
cancer had the lowest 5-year relative survival (6%) of 30
classified tumours in the United States of America [9]. In
2008, pancreatic cancer was the eighth cause of death
worldwide, accounting for 4% of all cancer deaths
(304,000) [10]. In Europe, pancreatic cancer is currently
the fifth (5.4%) cause of death from cancer in males and
the fourth (6.7%) in females [11].
The aim of the present study was to compare the
impact of ‘standard cancer care þ systematic EPC’ with
that of ‘standard cancer care þ on-demand EPC’ on
patient-reported outcomes, use of health services and
quality of end-of-life care in patients with advanced
gastric or pancreatic cancer who were candidates for
antitumour treatment. This paper presents the clinical
results from the pancreatic study population.
2. Materials and methods
2.1. Study design
From October 2012 to February 2015, we randomly
enrolled patients with newly diagnosed metastatic
pancreatic cancer to a multicentre, randomised study to
receive either ‘standard cancer care plus on-demand
EPC’ (standard arm) or ‘standard cancer care plus sys-
tematic EPC’ (interventional arm). The study was
approved by the Ethics Committee of the participating
centres and all patients provided written informed con-
sent (ClinicalTrials.gov NCT01996540).
2.2. Patient selection
Eligibility criteria were as follows: diagnosis of inoper-
able locally advanced and/or metastatic pancreatic
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age 18 years; Eastern Cooperative Oncology Group
(ECOG) performance status 0e2; life expectancy >2
months; and candidate for antitumour treatment
(chemotherapy or target therapy). All newly referred
patients were considered for participation in the study.
Patients who were already receiving PC, who had
received prior chemotherapy for metastatic or advanced
disease, or who had participated in a clinical trial were
not eligible.
2.3. Randomisation
Eligible patients were randomised for a maximum of 8
weeks after diagnosis and before anticancer treatment to
one of the two groups on a 1:1 allocation rate. Separate
randomisation lists using a permuted block balanced
procedure were generated for each participating centre.
No masking was involved in this open-label trial.
2.4. Study treatment and procedures
Patients assigned to the interventional arm had an
appointment scheduled with a PC specialist who had a
predefined checklist of issues to be addressed during the
consultation. The use of the checklist by the individual
researcher was not monitored from the outside, but re-
ported by the researcher himself. The checklist of topics
to be discussed during the visit of PC is the same used by
Temel [4] and is reported in the original protocol.
Patients met a member of the PC team within 2 weeks
of enrolment and were seen thereafter every 2e4 weeks
until death. In both arms, availability between ap-
pointments not scheduled in the protocol, but according
to the clinical and organisational solutions, was present
in every centre. Moreover, every researcher could have
adjunctive routine tools of assessment, not considered in
the present study.
PC appointments and interventions were oriented by
general PC guidelines [12]. The full-time PC specialist
who regularly saw interventional arm patients could
prescribe drugs and request other interventions per-
taining to physical, psychological, and spiritual needs.
However, recommendations made by the PC expert on
decision making processes had to be shared by the
oncologist. Patients assigned to the standard arm were
not scheduled to meet the PC team unless they, their
families, or the attending oncologist requested an
appointment. After the evaluation period (T1Z 12  3
weeks from T0), patients were followed by the PC team
as needed.
After informed consent was obtained (T0 Z date of
randomisation), patients completed the QoL and mood
questionnaires. At T1 (12  3 weeks from T0), infor-
mation on ECOG performance status, QoL, mood and
family satisfaction about care was recorded. After the
patient’s death (T2), information on the use of healthservices and EoL care, including anticancer therapy,
referral to hospice, hospital admissions, emergency
department visits, and the date and location of death,
was collected.
2.5. Measures
Health-related QoL and physical symptoms were
measured using the Functional Assessment of Cancer
Therapy e Hepatobiliary (FACT-Hep) scale [13].
The FACT-Hep scale assesses generic QoL concerns
(physical, social, emotional and functional well-being)
and disease-specific issues (Hepatobiliary Cancer Sub-
scale [HCS]). FACT-Hep scores range from 0 to 180 and
HCS scores range from 0 to 72 (higher score is better).
The Trial Outcome Index (TOI) combines the scores of
physical, functional and disease-specific subscales [14]
(score range 0e128).
Mood was assessed using the Hospital Anxiety and
Depression Scale (HADS), a 14-item instrument
composed of 2 subscales that screens for symptoms of
anxiety and depression (score range 0e21, higher score
indicates greater anxiety or depression; score >7 in-
dicates borderline or clinical anxiety or depression) [15].
The impact of family satisfaction about care was
evaluated by Italian version of the Family Satisfaction
with the End-of-Life Care (FAMCARE) questionnaire.
The FAMCARE is a 20-item scale and includes 4 sub-
scales: information giving, physical patient care, psy-
chosocial care and availability of care. Scores range from
20 to 100: the lower the score, the higher the family
satisfaction [16]. The caregivers were considered ‘the in-
dividual identified by the patient as the person most
involved in the care of the patient. The relationship with
the patient could be biological, legal, or functional’ [17].
Licenses to use the Italian versions of the FACT-Hep
and HADS questionnaires were obtained.
2.6. Statistical analysis
Theprimary objective of the studywas to assess the effects
of systematic EPC versus on-demand EPC consultation
during standard cancer care on QoL and clinical symp-
toms. The TOI score evaluation was the primary end-
point. Secondary objectives were symptom burden relief
and mood, family satisfaction about care, use of health-
care services location of death and overall survival (OS).
End-points were the percentage of patients with anxiety
and/or depression, the impact of family satisfaction about
care, the use of healthcare services and OS.
The study was designed to enroll 240 patients with
advanced gastric or pancreatic cancer who were candi-
dates for antitumour treatment. This report presents the
clinical results from the only pancreatic study population.
We estimated that, with 120 patients, the study would
have 80% power to detect a significant between-group
difference in the change in the TOI score between T0
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viation (SD). We computed effect sizes as standardised
mean differences (Cohen’s d); effect size of at least 0.3
was considered clinically relevant.
Differences in clinical outcomes between study
groups were assessed with the chi-square test for cate-
gorical variables and the Student’s t-test or non-
parametric ranking statistics (median test) for contin-
uous variables.
OS was defined as the time from the date of ran-
domisation to the date of death due to any cause. Pa-
tients who were still alive at the time of analysis
(February 2016) were censored at their last date of
follow-up. OS and 95% confidence intervals (95% con-
fidence interval [CI]) were estimated with the
KaplaneMeier product-limit method.
The statistical analysis on the primary outcome (the
change in the TOI score between T0 and T1) was per-
formed by applying the multiple imputation method in
order to handle missing data to achieve valid statistical
inference [18].
All analyses were performed on an intention-to-treat
population meeting eligibility criteria, adjusted for
baseline values. All tests were two sided at a significance
level of 0.05. No interim analysis was planned and no
multiplicity test correction was performed. All statistical
analyses were performed using SAS Statistical Software
version 9.4 (SAS Institute, Cary, NC, USA).Fig. 1. Flow chart of the study (CONsolidated Stand3. Results
Between October 2012 and February 2015, 207 patients
with advanced and/or metastatic pancreatic cancer were
recruited in 21 Italian centres. Twenty-one (10%) pa-
tients were not considered for analysis at T0 for various
reasons (Fig. 1), leaving 186 eligible patients (89 in the
standard arm and 97 in the interventional arm). The
most frequent reasons for not administering chemo-
therapy, after informed consent was obtained, were
patient refusal or a rapid worsening of clinical condi-
tions. Baseline characteristics of patients enrolled in the
two arms were superimposable (Table 1). From the date
of the first randomised patient until February 2016, all
patients received at least one PC consultation, those in
the interventional arm seeing the PC specialist more
often than standard arm patients (mean 8.9 consulta-
tions (SD 4.2, range 1e16) versus 3.9 (SD 3.3, range
1e10), respectively). Data referring to the period T0eT1
are as follows: mean value for interventional arm 5.1
(SD 1.6, range 1e11) and for standard arm 0.8 (SD 1.5,
range 0e8).
Fifty-seven of the 186 evaluable patients at T0 did not
complete QoL and mood questionnaires at T1 because
they were too ill or had died (24 patients in standard
arm and 33 in the interventional arm).
The mean change in TOI scores from baseline to 3
months was 4.47 (SD 14.12) for standard arm patientsards of Reporting Trials [CONSORT] diagram).
Table 1
Baseline characteristics of the study participants (n Z 186).
Standard
arm (n Z 89)
Interventional
arm (n Z 97)
n (%) n (%)
Median age, years (range) 66 (31e84) 67 (43e85)
Gender
Male 47 (52.8) 59 (61.5)
Female 42 (47.2) 37 (38.5)
Marital status
Married 59 (78.6) 70 (76.9)
Single 5 (6.7) 8 (8.8)
Divorced or separated 5 (6.7) 4 (4.4)
Widowed 6 (8.0) 9 (9.9)
Unknown/missing 14 6
ECOG performance status
0 50 (56.2) 55 (56.7)
1 35 (39.3) 36 (37.1)
2 4 (4.5) 6 (6.2)
Assessment of mood symptoms
HADS anxiety subscale
Normal (7) 45 (53.6) 54 (58.7)
Abnormal (>7) 39 (46.4) 38 (41.3)
HADS depression subscale
Normal (7) 50 (59.5) 69 (75.0)
Abnormal (>7) 34 (40.5) 23 (25.0)
Scores on QoL measures Mean value (SD) Mean value (SD)
FACT-Hep 117.5 (22.9) 120.6 (20.8)
HCS 50.5 (9.2) 51.8 (8.8)
TOI 82.6 (18.1) 85.1 (16.8)
Abbreviations: ECOG Z Eastern Cooperative Oncology Group;
FACT-Hep Z Functional Assessment of Cancer Therapy e Hep-
atobiliary; HADSZHospital Anxiety and Depression Scale;
QoLZ quality of life; HCSZHepatobiliary Cancer Subscale;
SDZstandard deviation; TOI Z Trial Outcome Index.
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with a difference between groups of 3.83 (95% CI
0.10e7.57) (p Z 0.041) (Table 2).Table 2
Mean change in QoL scores between T0 and T1.





FACT-Hep score 4.49 (17.68) 0.92 (13.01)
HCS score 2.23 (7.70) 0.28 (6.47)
TOI score 4.47 (14.12) 0.63 (10.95)
Abbreviations: QoLZ quality of life; CIZ confidence interval; FACT-H
HCSZHepatobiliary Cancer Subscale; SDZ standard deviation; TOI Z
Table 3
QoL outcomes at T1 (12  3 weeks).
Standard arm Interventional arm
Mean value (SD)
FACT-Hep score 113.0 (26.7) 119.6 (21.1)
HCS score 48.2 (11.2) 52.0 (8.4)
TOI score 78.1 (21.3) 84.4 (16.3)
Abbreviations: QoLZ quality of life; CIZ confidence interval; FACT-H
HCSZHepatobiliary Cancer Subscale; SDZ standard deviation; TOI Z
a Adjusted for baseline scores.Also, the mean change in HCS scores from baseline
to 3 months was 2.23 (SD 7.70) for standard arm
patients and 0.28 (6.47) for those in the interventional
arm (difference between groups of 2.51, 95% CI
0.40e4.61, p Z 0.013) (Table 2).
Mean values of FACT-Hep, HCS and TOI scale at
T1 were significantly better for patients enrolled in the
interventional arm (Table 3), especially in the latter two
scores (adjusted for baseline QoL values, pZ 0.008 and
p Z 0.022, respectively).
With regard to mood, HADS anxiety subscale
showed 64.1% of normal value for interventional arm
versus 47.7% of normal value for control arm. Depres-
sion subscale showed 65.7% of normal values for inter-
ventional arm and 55.4% of normal value for control
arm. However, none of those differences got a statisti-
cally significant p value (0.062 for anxiety and 0.281 for
depression, respectively) (Table 4), also after adjusting
for baseline mood values (p Z 0.108 for anxiety and
p Z 0.164 for depression).
For anxiety symptoms, the percentage of patients at
T1 that moved from a normal to abnormal values was
18.5% for the interventional arm and 16.3% for the
standard arm, respectively; on the contrary, the per-
centage of patients that moved from abnormal to
normal group was 34.2% in the interventional arm and
13.5% in the standard arm.
For depression, changes in the category were super-
imposable between the two arms. Also in relation to
family satisfaction with care received, there were no
differences in values (data not shown).
When the results of the study were evaluated
(February 2016), 143 (76.9%) of the 186 evaluable pa-
tients had already died. Overall survival probability atDifference between interventional




3.57 (1.02 to 8.15) 0.176
2.51 (0.40 to 4.61) 0.013
3.83 (0.10 to 7.57) 0.041
ep Z Functional Assessment of Cancer Therapy e Hepatobiliary;
Trial Outcome Index.
Difference between interventional
and standard arms (95% CI)
p Valuea Effect size
6.63 (0.47 to 13.73) 0.080 0.30
3.78 (0.86 to 6.71) 0.008 0.42
6.35 (0.75 to 11.95) 0.022 0.36
ep Z Functional Assessment of Cancer Therapy e Hepatobiliary;
Trial Outcome Index.
Table 4
Mood symptoms at T1 (12  3 weeks).
Standard arm Interventional arm P Value
n (%) n (%)
Assessment of mood symptoms
HADS anxiety subscale
Normal (7) 31 (47.7) 41 (64.1)
Abnormal (>7) 34 (52.3) 23 (35.9) 0.062
HADS depression subscale
Normal (7) 36 (55.4) 42 (65.7)
Abnormal (>7) 29 (44.6) 22 (34.3) 0.281
Abbreviation: HADSZHospital Anxiety and Depression Scale.
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interventional arm and 32% (95% CI 22e41) for the
standard arm population. The difference was not sta-
tistically significant.
In patients who died, we evaluated end-of-life care
aggressiveness as indirect indicator of the impact of EPC
on decision making during the final stage of the disease.
In a preliminary analysis, according to data available up
to now, standard arm versus interventional arm major
data were as follows: chemotherapy in the last 30 days of
life 27.8% versus 18.7% (pZ 0.192); median duration of
hospice admission 14 d versus 20 d (p Z 0.237); and
death at home or in hospice 66.7% versus 77.8%
(pZ 0.138). However, definitive results will be object of
a specific paper.4. Discussion
The primary aim of our study was to compare the effect
of systematic EPC and on-demand EPC consultation on
QoL during standard cancer care in patients with
advanced pancreas cancer. All the studies performed on
this topic had a control arm in which PC was performed
on demand, compared with an interventional arm in
which PC was given systematically. Of three major
randomised trials that demonstrated the efficacy of
systematic EPC [3e5], ours most closely resembles the
study of Temel et al. [4] which focused on EPC in
metastatic lung cancer which, like pancreas cancer, is a
disease with a survival expectancy of less than 12
months and an immediately high symptomatic burden
[4,19]. When we began the study, the results available on
EPC performed simultaneously with the best standard
cancer care, albeit scanty, suggested the usefulness of the
combination [1,5].
It is now a routine practice for oncologists to call in a
PC expert when they do not feel equipped to deal alone
with a situation, e.g. when patients and/or family
members ask for support for a physical, psychological,
relational or spiritual issue [7,20e22]. A control
arm in which on-demand PC consultations are often
followed by direct intervention from the PC group
could be considered as poorly differentiated from theinterventional arm. However, our study showed positive
results in terms of its primary aim, i.e. QoL, mainly with
regard to physical aspects. This is understandable as
advanced pancreatic cancer has an immediate heavy
physical burden on patients. EPC would probably have
a greater impact on psychological rather than physical
symptoms in tumours with a longer advanced phase.
A study by Zimmermann et al. [5] conducted on 461
patients with different solid tumours compared standard
care (conventional arm) with standard care þ EPC
(interventional arm) consisting of monthly PC consulta-
tions and the possibility of contacting PC specialists by
phone. The primary aim of Zimmerman’s study, QoL
evaluation after 3 months, showed a trend towards
improved QoL in the interventional arm that became
statistically significant after 4 months. Overall, the
interventional arm resulted in a reduced symptom burden
at 4 months, greater satisfaction with some areas of care
at different time points, and a better use of healthcare
services. In our study, QoL was impacted by interven-
tion, although mainly in its physical components.
The first two studies by Bakitas et al. [3,23] compared
standard care alone with standard care þ EPC in 322
patients with advanced cancer in a rural setting. EPC
consisted in a structured multicomponent nurse-led
intervention. The studies showed changes in favour of
the interventional arm in QoL and depression, a positive
trend for symptomburden, but no differences in the use of
healthcare services. In our experience, impact of system-
atic EPC on mood was detectable, but not significant.
A subsequent study by Bakitas et al. [24] focused on
early versus delayed activation of EPC. Although the
majority of outcomes evaluated did not show significant
differences, 1-year survival was better in the early acti-
vation arm. Moreover, a statistical advantage was seen
in depression experienced by family caregivers [25].
There has been much discussion about the reason for
the positive impact of EPC on overall survival. Some
correlate it with the benefit of EPC on QoL and
depression as both characteristics have been shown to be
correlated with overall survival [4,26]. An EPC strategy
may also facilitate a more appropriate decision-making
process.
The studies by Temel et al. [4,26] showed an advan-
tage in the interventional arm with regard to QoL,
depression and survival. Moreover, although not pow-
ered to assess specific differences in aggressiveness of
end-of-life care, other works by the same authors re-
ported a reduction in intravenous chemotherapy
administered in the 14 d before death [27], a longer
hospice stay [4] and improved prognosis awareness [19].
A potential weakness of our study stems from the fact
that the majority of the cancer centres involved were
members of the ‘Italian Association ofMedical Oncology
e Palliative Care Working Group’ [21] and accredited as
‘Designated Centres of Integrative Oncology and Pallia-
tive Care’ by the European Society of Medical Oncology
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symptom management and PC. Thus, the centre profiles
may have reduced the impact of the interventional arm.
Our EPC intervention also involved a single physician
expert in PC rather than a full multidisciplinary PC team
[28]. Recommendations made by the PC expert concern-
ing decision-making processes had to be accepted by the
oncologist, possibly reducing the effectiveness of the
intervention [4,29]. A further weakness is that, although
we advised all centres to complete a predefined checklist
on issues to be addressed during the PC consultation, we
did not check to ensure that this had been done. Finally,
our study was randomised but not blinded. Although
patient blinding is not possible, blinding of the assessor
could be used in future studies.
Our study also has some strengths. Whilst some au-
thors chose a cluster study design due to the difficulty of
randomising single patients in this clinical setting [5], we
performed individual randomisation. Furthermore, the
majority of previous studies were mono-institutional
and carried out in large, research-oriented centres,
whereas ours was a multicentric study involving both
large cancer centres and small community-based centres.
As far as we know, this was also the first study dedicated
solely to the evaluation of EPC in advanced pancreatic
cancer patients.
It has been reported that different referral modalities
for EPC have been assessed, as some ways of addressing
a patient to PC services can be identified: on spontane-
ously referred symptom on request activation, from
patient and/or the attending physician (the conventional
one), on symptom request actively searched by a
screening tool [30] and automatically in all patients in a
definite situation (i.e. metastatic solid tumour disease).
Our study assessed the comparison between a sys-
tematic activation of EPC in a single cancer population
versus spontaneously presented on-demand need and
showed an impact of the former on QoL, mainly in the
physical aspects. Larger comparisons in different tu-
mours including the other modalities can represent
further steps of research in his field, also including
impact on EoL PC items, and costs.5. Panel: research in context
5.1. Evidence before this study
EPC together with standard oncological care has been
assessed with respect with different outcomes: QoL,
quality of care, and costs. While QoL assessment mainly
reflects the impact of EPC on patient outcomes at the
moment when EPC delivered, evaluation of quality of
care and costs imply that EPC can have, thorough a
shared (patient/family e oncologist e PC physician)
decision-making process, an impact on aggressiveness in
end-of-life care. Even though evidence of impact of EPCon such outcomes has been studiedwith clinical studies by
a variety of methodologies, the number of randomised
clinical trials has so far still limited, and the evidence of
impact of EPC is still uneven. We searched the relevant
literature on PubMed until February 2016 using ‘early
palliative care’ and ‘oncology’ and ‘randomised clinical
trial’ and completed our investigation with hand search
on the basis of the paper we found. We found all the
relevant literature, both for original papers and system-
atic review, up to the most recently published.
As mentioned above, the evidence of efficacy of EPC
is sparse. Most papers assessing different outcomes
showed positive results for certain outcomes and nega-
tive for others (sometimes the positive result did not
regard the primary outcome of the study, but secondary
ones). However, globally, the evidence has been evalu-
ated enough from different agencies (American Society
for Clinical Oncology and European Society for Medical
Oncology) to suggest the inclusion of the EPC in stan-
dard cancer care, with the recommendation to imple-
ment and increase the overall body of evidence.
5.2. Added value of this study
Our study is aimed to suggest change in oncological
clinical practice concerning care of pancreas cancer pa-
tients. The study was conducted in a definite population
of patients with cancer of pancreas, in metastatic or
locally advanced unresectable phase, about to set up for
a first-line chemotherapy. Our data show that systematic
EPC approach added to standard cancer care, when
compared with on-demand EPC added to standard
cancer care, shows advantages in term of QoL, mainly in
the physical subscale. In literature, there was not a
specifical study on pancreas cancer, but only in other
specific populations (lung), or in mixed cancer patient
populations.
5.3. Implications of the available evidence
Systematic EPC in pancreas cancer patients is justified
to be proposed to patients and health services for its
advantage in QoL and physical symptoms.
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